- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05023837
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type (Esporta)
January 22, 2022 updated by: Yongchang Zhang, Hunan Province Tumor Hospital
Evaluation of the Efficacy of Immunotherapy in Uncommon Pathological Types of Lung Cancer
This study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world.
Through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University.
Retrospective study of 40 patients with advanced uncommon pathological types of lung cancer and observe the efficacy and safety of immune checkpoint inhibitor regimen in the real world.
The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.
Statistical analysis is used to compare the differences between the two treatments, so that patients can better choose treatment strategies.
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Advanced uncommon pathological types of lung cancer by histopathology
Description
Inclusion Criteria:
- 18,Advanced uncommon pathological types of lung cancer by histopathology whether or not it is accompanied by a driver mutation Treatment Plan is pembrolizumab 200mg iv q21d
Exclusion Criteria:
- Patients received antitumor treatment before Patients with contraindication of chemotherapy Pregnant or breast feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: may 2019- may 2021
|
progression survival time
|
may 2019- may 2021
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: may 2019- may 2021
|
over survival time
|
may 2019- may 2021
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 2, 2018
Primary Completion (Actual)
August 2, 2021
Study Completion (Actual)
August 3, 2021
Study Registration Dates
First Submitted
August 21, 2021
First Submitted That Met QC Criteria
August 21, 2021
First Posted (Actual)
August 27, 2021
Study Record Updates
Last Update Posted (Actual)
January 25, 2022
Last Update Submitted That Met QC Criteria
January 22, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Esporta
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncommon Pathological Types of Lung Cancer
-
Hospices Civils de LyonNot yet recruitingAll Types of Solid CancerFrance
-
Tel-Aviv Sourasky Medical CenterUnknownDifferent Types of CancerIsrael
-
Universität Duisburg-EssenUniversity Hospital, Essen; Helios Hospital Krefeld; Oslo Centre for Biostatistics...RecruitingAll Types of Pediatric CancerGermany
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
-
SpeciCareUniversity of Washington; Georgia Institute of Technology; Predictive Oncology; Netnoid... and other collaboratorsRecruitingMelanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Hepatocellular Carcinoma | Transitional Cell Carcinoma | Glioblastoma Multiforme | Cholangiocarcinoma | Small-cell Lung Cancer | Oligodendroglioma | Cancer of Head and Neck | Cancer of Liver | Cancer of Pancreas | Cancer of Brain and Nervous System | Adrenal... and other conditionsUnited States
-
Centre hospitalier de l'Université de Montréal...Pentax MedicalCompletedColo-rectal Cancer | Polyps of ColonCanada
-
Mayo ClinicMedtronic - MITGTerminatedLung Neoplasms | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | Metastatic Cancer to the LungUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); United States Department of Defense; National...RecruitingLung Cancer | Cancer of ThoraxUnited States
-
National Cancer Institute (NCI)CompletedSquamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer | Adenosquamous Cell Lung CancerUnited States
Clinical Trials on Pembrolizumab 100 MG Injection
-
Juventas Therapeutics, Inc.UnknownIschemic Heart FailureUnited States
-
Sotiria General HospitalUnknownSevere Eosinophilic AsthmaGreece
-
Taivex Therapeutics CorporationRecruitingSafety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid TumorsAdvanced Solid TumorTaiwan
-
Almirall, S.A.Completed
-
Jair Bar, M.D., Ph.D.Merck Sharp & Dohme LLCCompletedNon Small Cell Lung Carcinoma | Stage II | Stage IIsrael
-
Mansoura Integrated Fertility CenterCompleted
-
AstraZenecaCompleted
-
Revogenex, Inc.Suspended
-
Shanghai Henlius BiotechActive, not recruiting
-
Universitair Ziekenhuis BrusselRecruitingSolid Tumor | Non Small Cell Lung CancerBelgium